CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $532,138 | +157.1% | 17,893 | +38.9% | 0.12% | +7.1% |
| Q1 2023 | $206,949 | -86.1% | 12,886 | -84.2% | 0.11% | -84.8% |
| Q4 2022 | $1,490,828 | +55.1% | 81,466 | +66.5% | 0.74% | +120.4% |
| Q3 2022 | $961,000 | -12.1% | 48,925 | -16.5% | 0.34% | -29.3% |
| Q2 2022 | $1,093,000 | -3.4% | 58,601 | +13.7% | 0.48% | -9.6% |
| Q1 2022 | $1,131,000 | -0.4% | 51,536 | +28.9% | 0.53% | +178.4% |
| Q4 2021 | $1,136,000 | – | 39,989 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |